Lyell Immunopharma (Nasdaq: LYEL) announced the completion of a manufacturing technology transfer for its LYL273 cancer therapy candidate to its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE